TheraCryf
plc
("TheraCryf", the "Company" or the "Group")
Posting of Annual Report and Notice of
AGM
Alderley Park, UK - 21 June 2024: TheraCryf plc
(AIM: TCF), the clinical stage drug
development company focussing on oncology and
neuropsychiatry, announces
that its Annual Report and Accounts for the year ended 31 March
2024 have been posted to shareholders and are now available on the
Company website.
Additionally, the Company's AGM will take place
on at 2.30 p.m. on Thursday 18 July 2024 in the Block 11 Lecture
Theatre, Alderley Park Conference Centre, Cheshire, United Kingdom,
SK10 4TG.
-Ends-
Enquiries
|
TheraCryf plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
|
+44 (0)1625 315
090
enquiries@theracryf.com
|
|
Cavendish Capital Markets (NOMAD and Broker)
Geoff Nash / Teddy Whiley / Rory Sale (Corporate
Finance)
Nigel Birks / Harriet Ward
(ECM)
|
+44 20 7220
0500
|
|
Instinctif Partners
Melanie
Toyne-Sewell / Jack Kincade
|
+44 207 457 2020
theracryf@Instinctif.com
|
About TheraCryf plc
TheraCryf is the clinical stage drug
development company focussing on oncology and neuropsychiatry. The
Company has a broad clinical and preclinical pipeline in
indications including glioblastoma* neurodevelopmental disorders,
addiction, anxiety and narcolepsy* [*orphan
indications].
Its strategy is to generate
compelling data sets to preclinical and/or clinical proof of
concept and partner its clinical programmes with mid-size to large
pharma for larger trials and commercialisation. As well as a number
of industry partnerships with companies, including Stalicla SA, in
neurodevelopmental disorders. The Company has sourced know
how for programmes from companies such as Shire (now
Takeda).
TheraCryf has worked with and has
ongoing collaborations with major universities and hospitals such
as the University of Manchester, La Sapienza (Università di Roma),
the Erasmus Medical Centre, Rotterdam, Kings College London and
University of Connecticut.
The Company has its headquarters and
registered office at Alderley Park, Cheshire. It is listed on AIM
in London and trades under the ticker symbol TCF.
For further information, please
visit: www.theracryf.com